Results 161 to 170 of about 11,204,640 (258)

Spatial heterogeneity of hotspot mutations and clonal relatedness in ovarian endometrioid carcinoma

open access: yesMolecular Oncology, EarlyView.
Spatially resolved analysis revealed heterogeneous distributions of selected cancer‐associated mutations within ovarian endometrioid carcinomas. Shared mutations between paired endometrial and ovarian tumors supported clonal relatedness. These findings highlight the value of sampling multiple tumor regions when interpreting molecular profiles ...
Takahito Ashihara   +10 more
wiley   +1 more source

Tumour‐proximal deep serum proteomics identifies biomarkers associated with ovarian cancer

open access: yesMolecular Oncology, EarlyView.
New biomarkers are needed for early ovarian cancer detection. Ovarian (tumour‐proximal) and peripheral vein serum from healthy women and patients with benign or malignant tumours underwent nanoparticle‐enriched deep proteomics. Ovarian serum yielded more protein identifications and revealed tumour‐reflective signatures.
Darren Lau   +9 more
wiley   +1 more source

The impact of leukocyte‐associated RNA retention on platelet RNA‐based cancer detection

open access: yesMolecular Oncology, EarlyView.
Platelets carry RNA signals that may help detect cancer, but platelet samples can also retain RNA from white blood cells. We found that this retained white blood cell signal did not significantly affect machine learning cancer classification, suggesting that the cancer‐related RNA signal in platelets is largely independent of leukocyte‐associated RNA ...
Michał Sieczczyński   +12 more
wiley   +1 more source

Overcoming platinum resistance by the disulfiram metabolite CuET in novel preclinical models of human carcinomas

open access: yesMolecular Oncology, EarlyView.
Cisplatin‐resistant cancer cells survive DNA‐damaging platinum‐based treatment yet remain sensitive to CuET‐induced proteotoxic stress. The distinct mechanism of action allows CuET to overcome and eliminate cisplatin‐resistant tumour cells, unless highly expressed metallothioneins (MTs) interfere with CuET, thereby highlighting MT levels as candidate ...
Stefanos Arampatzis   +20 more
wiley   +1 more source

Immune potentiating effects of the HDAC inhibitor Zabadinostat on human immune and tumor cells

open access: yesMolecular Oncology, EarlyView.
Zabadinostat (CXD101) is a second‐generation class I histone deacetylase inhibitor (HDACi). We show that Zabadinostat activates human T cells and natural killer cells while reducing frequencies and function of regulatory T cells. Zabadinostat also increases T cell stemness and modulates tumor cell phenotype to potentially enhance immune recognition ...
Stephanie C. Pitts   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy